Copyright Reports & Markets. All rights reserved.

Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 Tedizolid Phosphate
      • 1.2.2 Ceftolozane/Tazobactam
      • 1.2.3 Ceftazidime/Avibactum
      • 1.2.4 Amikacin Inhale
      • 1.2.5 Plazomicin
      • 1.2.6 Synflorix Vaccine
    • 1.3 Market Analysis by Applications
      • 1.3.1 Bacterial Pneumonia
      • 1.3.2 Viral Pneumonia
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2014-2024)
        • 1.4.1.2 Canada Market States and Outlook (2014-2024)
        • 1.4.1.3 Mexico Market States and Outlook (2014-2024)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2014-2024)
        • 1.4.2.2 France Market States and Outlook (2014-2024)
        • 1.4.2.3 UK Market States and Outlook (2014-2024)
        • 1.4.2.4 Russia Market States and Outlook (2014-2024)
        • 1.4.2.5 Italy Market States and Outlook (2014-2024)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2014-2024)
        • 1.4.3.2 Japan Market States and Outlook (2014-2024)
        • 1.4.3.3 Korea Market States and Outlook (2014-2024)
        • 1.4.3.4 India Market States and Outlook (2014-2024)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2014-2024)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2014-2024)
        • 1.4.4.2 Egypt Market States and Outlook (2014-2024)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2014-2024)
        • 1.4.4.4 South Africa Market States and Outlook (2014-2024)
        • 1.4.4.5 Turkey Market States and Outlook (2014-2024)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Achaogen
      • 2.1.1 Business Overview
      • 2.1.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Achaogen Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.2 Aridis Pharmaceuticals
      • 2.2.1 Business Overview
      • 2.2.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.2.2.1 Product A
        • 2.2.2.2 Product B
      • 2.2.3 Aridis Pharmaceuticals Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.3 AstraZeneca
      • 2.3.1 Business Overview
      • 2.3.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.3.2.1 Product A
        • 2.3.2.2 Product B
      • 2.3.3 AstraZeneca Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.4 Cubist Pharmaceuticals
      • 2.4.1 Business Overview
      • 2.4.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.4.2.1 Product A
        • 2.4.2.2 Product B
      • 2.4.3 Cubist Pharmaceuticals Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.5 Meiji Seika Pharma
      • 2.5.1 Business Overview
      • 2.5.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.5.2.1 Product A
        • 2.5.2.2 Product B
      • 2.5.3 Meiji Seika Pharma Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.6 Merck
      • 2.6.1 Business Overview
      • 2.6.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.6.2.1 Product A
        • 2.6.2.2 Product B
      • 2.6.3 Merck Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.7 Sanofi
      • 2.7.1 Business Overview
      • 2.7.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.7.2.1 Product A
        • 2.7.2.2 Product B
      • 2.7.3 Sanofi Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.8 GlaxoSmithKline
      • 2.8.1 Business Overview
      • 2.8.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.8.2.1 Product A
        • 2.8.2.2 Product B
      • 2.8.3 GlaxoSmithKline Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)
    • 2.9 Valneva
      • 2.9.1 Business Overview
      • 2.9.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Type and Applications
        • 2.9.2.1 Product A
        • 2.9.2.2 Product B
      • 2.9.3 Valneva Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2017-2018)

    3 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2017-2018)

    • 3.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Manufacturer (2017-2018)
    • 3.2 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Manufacturer (2017-2018)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Manufacturer Market Share in 2018
      • 3.3.2 Top 6 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Manufacturer Market Share in 2018
    • 3.4 Market Competition Trend

    4 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Analysis by Regions

    • 4.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Regions (2014-2019)
      • 4.1.2 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Regions (2014-2019)
    • 4.2 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 4.3 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 4.4 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 4.5 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 4.6 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    5 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs by Country

    • 5.1 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Country
      • 5.1.1 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Country (2014-2019)
      • 5.1.2 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Country (2014-2019)
    • 5.2 United States Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 5.3 Canada Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 5.4 Mexico Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    6 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs by Country

    • 6.1 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Country
      • 6.1.1 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Country (2014-2019)
      • 6.1.2 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Country (2014-2019)
    • 6.2 Germany Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 6.3 UK Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 6.4 France Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 6.5 Russia Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 6.6 Italy Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    7 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs by Country

    • 7.1 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Country
      • 7.1.1 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Country (2014-2019)
      • 7.1.2 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Country (2014-2019)
    • 7.2 China Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 7.3 Japan Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 7.4 Korea Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 7.5 India Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 7.6 Southeast Asia Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    8 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs by Country

    • 8.1 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Country
      • 8.1.1 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Country (2014-2019)
      • 8.1.2 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Country (2014-2019)
    • 8.2 Brazil Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 8.3 Argentina Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 8.4 Colombia Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    9 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs by Countries

    • 9.1 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Country
      • 9.1.1 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Country (2014-2019)
      • 9.1.2 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Country (2014-2019)
    • 9.2 Saudi Arabia Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 9.3 Turkey Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 9.4 Egypt Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 9.5 Nigeria Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)
    • 9.6 South Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Growth Rate (2014-2019)

    10 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Segment by Type

    • 10.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Market Share by Type (2014-2019)
      • 10.1.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales and Market Share by Type (2014-2019)
      • 10.1.2 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Revenue and Market Share by Type (2014-2019)
    • 10.2 Tedizolid Phosphate Sales Growth and Price
      • 10.2.1 Global Tedizolid Phosphate Sales Growth (2014-2019)
      • 10.2.2 Global Tedizolid Phosphate Price (2014-2019)
    • 10.3 Ceftolozane/Tazobactam Sales Growth and Price
      • 10.3.1 Global Ceftolozane/Tazobactam Sales Growth (2014-2019)
      • 10.3.2 Global Ceftolozane/Tazobactam Price (2014-2019)
    • 10.4 Ceftazidime/Avibactum Sales Growth and Price
      • 10.4.1 Global Ceftazidime/Avibactum Sales Growth (2014-2019)
      • 10.4.2 Global Ceftazidime/Avibactum Price (2014-2019)
    • 10.5 Amikacin Inhale Sales Growth and Price
      • 10.5.1 Global Amikacin Inhale Sales Growth (2014-2019)
      • 10.5.2 Global Amikacin Inhale Price (2014-2019)
    • 10.6 Plazomicin Sales Growth and Price
      • 10.6.1 Global Plazomicin Sales Growth (2014-2019)
      • 10.6.2 Global Plazomicin Price (2014-2019)
    • 10.7 Synflorix Vaccine Sales Growth and Price
      • 10.7.1 Global Synflorix Vaccine Sales Growth (2014-2019)
      • 10.7.2 Global Synflorix Vaccine Price (2014-2019)

    11 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Segment by Application

    • 11.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales Market Share by Application (2014-2019)
    • 11.2 Bacterial Pneumonia Sales Growth (2014-2019)
    • 11.3 Viral Pneumonia Sales Growth (2014-2019)

    12 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)

    • 12.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales, Revenue and Growth Rate (2019-2024)
    • 12.2 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast by Regions (2019-2024)
      • 12.2.1 North America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)
      • 12.2.2 Europe Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)
      • 12.2.3 Asia-Pacific Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)
      • 12.2.4 South America Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)
      • 12.2.5 Middle East and Africa Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast (2019-2024)
    • 12.3 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast by Type (2019-2024)
      • 12.3.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales Forecast by Type (2019-2024)
      • 12.3.2 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Share Forecast by Type (2019-2024)
    • 12.4 Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Forecast by Application (2019-2024)
      • 12.4.1 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Sales Forecast by Application (2019-2024)
      • 12.4.2 Global Pipeline Analysis of Hospital Acquired Pneumonia Drugs Market Share Forecast by Application (2019-2024)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Nosocomial or hospital acquired infections have created numerous complications for patients in hospitals throughout the world, as these infections are caused by multidrug resistant microorganisms, the recuperation of a patient is drastically reduced and accompanied by several comorbidities. Being multidrug resistant, these organisms are immune to the conventional antibiotics hence difficult to treat. Pneumonia is one of the prominent infections caused in hospital premises. Cases of hospital acquired pneumonia are common in immunocompromised patients, post surgical infections, enteral feeding, elderly and infant patients. As hospital acquired pneumonia is mainly caused as a result of prolonged exposure to ventilator air, it is also called as ventilator associated pneumonia. Major causative pathogens include methicillin resistant S. aureus (MRSA), multi drug resistant (MDR) P. aeruginosa, Klebsiella and Acinetobacter. Respiratory Syncytial Virus (RSV) has also been found to be a major causative agent of nosocomial pneumonia in new borne.  

      Scope of the Report:
      The worldwide market for Pipeline Analysis of Hospital Acquired Pneumonia Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
      This report focuses on the Pipeline Analysis of Hospital Acquired Pneumonia Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers
      Achaogen
      Aridis Pharmaceuticals
      AstraZeneca
      Cubist Pharmaceuticals
      Meiji Seika Pharma
      Merck
      Sanofi
      GlaxoSmithKline
      Valneva

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia etc.)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      Tedizolid Phosphate
      Ceftolozane/Tazobactam
      Ceftazidime/Avibactum
      Amikacin Inhale
      Plazomicin
      Synflorix Vaccine

      Market Segment by Applications, can be divided into
      Bacterial Pneumonia
      Viral Pneumonia

      The content of the study subjects, includes a total of 15 chapters:
      Chapter 1, to describe Pipeline Analysis of Hospital Acquired Pneumonia Drugs product scope, market overview, market opportunities, market driving force and market risks.
      Chapter 2, to profile the top manufacturers of Pipeline Analysis of Hospital Acquired Pneumonia Drugs, with price, sales, revenue and global market share of Pipeline Analysis of Hospital Acquired Pneumonia Drugs in 2017 and 2018.
      Chapter 3, the Pipeline Analysis of Hospital Acquired Pneumonia Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
      Chapter 4, the Pipeline Analysis of Hospital Acquired Pneumonia Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
      Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
      Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
      Chapter 12, Pipeline Analysis of Hospital Acquired Pneumonia Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
      Chapter 13, 14 and 15, to describe Pipeline Analysis of Hospital Acquired Pneumonia Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

      Buy now